AHK-Cu vs GHK-Cu: One Amino Acid Apart, Far Apart on Evidence

AHK-Cu and GHK-Cu are copper complexes of two tripeptides that differ by a single amino acid — and by a very large gap in how much research stands behind each. GHK-Cu is a naturally occurring plasma peptide with a substantial body of cell, explant and topical cosmetic work. AHK-Cu is a synthetic analogue whose directly relevant published evidence comes down, in practice, to laboratory work on hair follicles and skin cells.

The structural difference

GHK is glycine–histidine–lysine. AHK is alanine–histidine–lysine. The only change is at the first position, where alanine replaces glycine — glycine's side chain is a single hydrogen atom, alanine's is a methyl group. The histidine in the middle and the lysine at the end are shared.

That shared histidine is what matters for copper. Both peptides bind copper(II) the same way, through the histidine imidazole ring and the terminal amine, and for both the copper complex rather than the free peptide is considered the active form. That common chemistry is why they are grouped together as copper peptides.

It also means the "-Cu" matters. The library's GHK-Cu profile makes the point explicitly: copper is pharmacologically active in its own right, and evidence for the complex is not evidence for the uncomplexed peptide, which is also sold. The same caution applies to AHK.

AHK-Cu vs GHK-Cu side by side

Full profiles: GHK-Cu and AHK-Cu.

What GHK-Cu's evidence covers

GHK-Cu's research base starts from an observation rather than an invention: GHK is a tripeptide found in human plasma, first isolated by Pickart, and plasma concentrations fall substantially with age. The field is built on the question of what the peptide does and whether restoring it matters.

The evidence sits at three tiers, and they should not be blurred together.

In vitro and explant. In fibroblast and skin explant studies, the copper complex modulates matrix metalloproteinases and their tissue inhibitors, stimulates collagen and glycosaminoglycan synthesis, and shifts a broad set of inflammatory and remodelling genes (Pickart and Margolina 2018). Copper is also a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, which may account for part of the effect. In liposome formulation work, GHK-Cu inhibited elastase in a test-tube assay (Dymek 2023).

Animal. Beyond skin, GHK-Cu reduced inflammatory cytokines and tissue damage in a mouse model of chemically induced colitis (Mao 2025). That is a rodent finding, not a human one.

Topical human. Every human study of GHK-Cu is topical. The randomised trial most often cited tested a GHK-Cu skincare regimen after CO2 laser resurfacing: blinded assessment found no significant difference in redness, wrinkles or overall skin quality compared with a regimen without it, though patients using GHK-Cu reported higher satisfaction (Miller 2006). A phase 2 trial of a topical GHK-Cu gel for acute wounds is registered and recruiting, with no results. These studies test finished products rather than a measured peptide dose.

Even topical delivery is not straightforward. GHK-Cu is fairly hydrophilic and permeates the stratum corneum poorly, which is why liposome carriers are being studied — and a 2025 review found that transport of GHK-Cu in liposomes across skin has received little attention so far (Ogórek 2025).

There is no human study of injected GHK-Cu at any dose. It is one of the unapproved peptides now marketed direct to patients, for which rigorous human safety data are scarce (Mendias and Awan 2026).

What AHK-Cu's evidence covers

The primary study most directly about AHK-Cu tested it on human hair follicles kept alive outside the body and on cultured dermal papilla cells — the specialised fibroblasts at the base of the follicle that drive its growth (Pyo 2007). It reported that AHK-Cu:

• stimulated elongation of isolated human hair follicles ex vivo;

• increased proliferation of dermal papilla cells in culture;

• raised the Bcl-2/Bax ratio and lowered cleaved caspase-3 and PARP, markers associated with reduced apoptosis.

One detail is worth keeping: the drop in the number of apoptotic cells itself was not statistically significant. The authors proposed that AHK-Cu promotes follicle growth by stimulating dermal papilla cell proliferation and preventing their apoptosis — a reasonable hypothesis from cell work, not a demonstration of hair growth in a person.

The library profile adds that AHK-Cu has been described as stimulating extracellular matrix production in fibroblast models, and that its evidence base is smaller than GHK-Cu's and predominantly in vitro and cosmetic. No controlled human trial has been published — not topical, not by any other route.

Skin versus hair

The usual shorthand is "GHK-Cu for skin, AHK-Cu for hair". It is accurate only as a description of where each has been studied, not as a result. GHK-Cu is also discussed in hair-follicle research, and AHK-Cu in skin cosmetic research. No study has put the two side by side in the same model, so there is no basis for saying either is better for anything. For the wider picture, see peptides for hair growth and peptides for skin.

Reported effects and what is not known about safety

Neither compound has been through the safety evaluation an approved drug receives, so there is no adverse-event profile in the sense a medicine has one. What the library records is short and largely descriptive.

For GHK-Cu, the effects listed are local irritation, a blue-green tint at high copper load, and injection-site reactions when it is injected — with the explicit caveat that injection is not an approved route for it. For AHK-Cu, the list is irritation and copper-related discolouration, and the profile classes it as cosmetic and research use only.

The shared issue is copper. It is part of the active molecule in both, and it is pharmacologically active in its own right, so exposure to the complex is also exposure to copper. How much that matters depends on route and quantity, and neither has been characterised for AHK-Cu at all. Absence of documented harm, for a compound nobody has studied in people, is not evidence of safety.

Handling and vial math

Both are supplied as copper complexes, and copper colours a solution: GHK-Cu is known to give a blue-green tint at high copper load, and discolouration is listed for AHK-Cu too. Colour shows that copper is present. It says nothing about identity, purity or quantity — that comes from a certificate of analysis, and the guide to reading a COA covers what to check.

Reconstitution is the same arithmetic as any lyophilised peptide: labelled mass divided by diluent volume gives a concentration. The peptide calculator does that, and the insulin syringe units converter turns a volume into syringe markings. Neither supplies a dose, because none exists for either compound. A percentage in a peptide serum is not a figure that converts into a vial calculation either.

What the evidence does not show

• A head-to-head comparison. No study has compared AHK-Cu with GHK-Cu.

• Any human trial of AHK-Cu. Its evidence is cells and isolated follicles in a dish.

• Hair regrowth on a scalp. Follicles lengthening ex vivo is an early signal, not a clinical outcome.

• Injectable effects for either. GHK-Cu's human evidence is topical, does not quantify a dose, and does not support injection.

• Transfer between compounds. GHK-Cu findings cannot be borrowed for AHK-Cu, and findings for either copper complex cannot be borrowed for the free peptide.

Frequently asked questions

What is the difference between AHK-Cu and GHK-Cu?

One amino acid: AHK-Cu has alanine where GHK-Cu has glycine. Both bind copper the same way. The larger difference is evidence — GHK-Cu has cell, animal and topical human studies, while AHK-Cu's published work is mainly in vitro hair-follicle and skin-cell research.

Is AHK-Cu better than GHK-Cu for hair growth?

There is no evidence either way. AHK-Cu lengthened isolated human hair follicles and increased dermal papilla cell proliferation in laboratory work, but it has no human trial, and no study has compared it with GHK-Cu.

Is AHK-Cu found naturally in the body?

No. GHK is a naturally occurring plasma tripeptide; AHK-Cu is a synthetic analogue made by swapping the first amino acid.

Is AHK-Cu a copper peptide?

Yes. It is the copper(II) complex of the tripeptide alanyl-histidyl-lysine, and like GHK-Cu the copper-bound form is considered the active one.

Are AHK-Cu or GHK-Cu FDA-approved?

Neither. GHK-Cu is a common cosmetic ingredient and AHK-Cu appears in cosmetic research, but neither is an approved drug, and injecting either is not an approved route.